Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

Shimrit Harlev, Nashwa Fadaos, Tehila Azoulay, Ronit Leiba, Nurit Horesh, Tsofia Inbar, Netanel A. Horowitz, Inna Tsoran-Rosenthal, Noa Lavi, Eldad J. Dann, Tsila Zuckerman

Blood (2022) 140 (Supplement 1): 6534–6535.

https://doi.org/10.1182/blood-2022-166233

Published: 2022

Journal Articles

In Patients with Acute Myeloid Leukemia, Hidac Administered on Days 1, 2 and 3 of Consolidation Course Is As Efficacious As Hidac Given on Days 1, 3 and 5, but Is Better Tolerated

Baher Krayem, Avraham Frisch, Nurit Horesh, Ronit Leiba, Tsila Zuckerman, Yishai Ofran

Blood (2021) 138 (Supplement 1): 3378.

https://doi.org/10.1182/blood-2021-152532

Published: 2021

Journal Articles

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Yishai Ofran, MD, Ronit Leiba, Dina Rosenberg, Israel Henig, MD, Dana Yehudai-Ofir, MD, Nuhad Haddad, MD, Riva Fineman, MD, Avraham Frisch, MD, Doaa Okasha, MD, Yariv Carasso, MD, Tsila Zuckerman, MD, Nurit Horesh, MD

Blood (2019) 134 (Supplement_1): 2603.

https://doi.org/10.1182/blood-2019-126553

Published: 2019

Journal Articles

Monoallelic Deletion of the Whole Locus of Immunoglobulin Heavy Chain Gene [Del(IGH)] Is Associated with a Better Prognosis in Newly Diagnosed Multiple Myeloma

Luba Trakhtenbrot, PhD, Adrian Duek, MD, Ninette Amariglio, PhD, Abraham Avigdor, MD, Noam Benyamini, MD, Izhar Hardan, MD, Itay Zilbershatz, MD, Chezi Ganzel, MD, Olga Shvetz, MD, Ronit Leiba, PhD, Marina Izak, MD, Cohen Ziv, Ba, Gabriela Rozic, PhD, Arnon Nagler, MD, Merav Leiba

Blood (2017) 130 (Supplement 1): 5368.

https://doi.org/10.1182/blood.V130.Suppl_1.5368.5368

Published: 2017

Journal Articles

Prognosis of Patients with Standard- or Intermediate-Risk Acute Myeloid Leukemia Presenting with Residual Disease after One Induction Cycle Is Improved If Remission Is Achieved Following Re-Induction Given By Day 14 Compared to Second-Line Therapy Given 24-40 Days after Induction

Avraham Frisch, MD, Ronit Leiba, MSc, Chezi Ganzel, Tsila Zuckerman, MD, Nuhad Haddad, MD, Riva Fineman, MD, Yishai Ofran, MD

Blood (2016) 128 (22): 3999.

https://doi.org/10.1182/blood.V128.22.3999.3999

Published: 2016

Journal Articles

Early Bone Marrow Examination, On The Fifth Day Of Induction For AML, Is Highly Predictive Of Response

Blood (2013) 122 (21): 3893.

https://doi.org/10.1182/blood.V122.21.3893.3893

Published: 2013

Journal Articles

Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era

Irit Avivi, MD, Ariel Zilberlicht, MD, Eldad J Dann, MD, Jacob M. Rowe, MD, Ronit Leiba, MSc., Tal Faibish, MSc, Rachel Bar-Shalom, MD

Blood (2011) 118 (21): 1576.

https://doi.org/10.1182/blood.V118.21.1576.1576

Published: 2011

Journal Articles

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Drorit Merkel, MD, Kalman Filanovsky, MD, Ariel Aviv, MD, Moshe E. Gatt, MD, Yair Herishanu, MD, Ariela Arad, MD, Tamar Tadmor, MD, Najib Dally, MD, Aharon Ronson, MD, Luiza Akria, MD, Andrei Braester, MD, Arnon Nagler, MD, Ronit Leiba, MSc., Yishai Ofran, MD

Blood (2011) 118 (21): 3811.

https://doi.org/10.1182/blood.V118.21.3811.3811

Published: 2011

NARROW

Administration of Obinutuzumab, and Not Rituximab, during Induction and Maintenance for Follicular Lymphoma Increases the Likelihood of Developing Delayed Neutropenia

In Patients with Acute Myeloid Leukemia, Hidac Administered on Days 1, 2 and 3 of Consolidation Course Is As Efficacious As Hidac Given on Days 1, 3 and 5, but Is Better Tolerated

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Monoallelic Deletion of the Whole Locus of Immunoglobulin Heavy Chain Gene [Del(IGH)] Is Associated with a Better Prognosis in Newly Diagnosed Multiple Myeloma

Prognosis of Patients with Standard- or Intermediate-Risk Acute Myeloid Leukemia Presenting with Residual Disease after One Induction Cycle Is Improved If Remission Is Achieved Following Re-Induction Given By Day 14 Compared to Second-Line Therapy Given 24-40 Days after Induction

Early Bone Marrow Examination, On The Fifth Day Of Induction For AML, Is Highly Predictive Of Response

Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era

Predictive Parameters for Infections During Azacitidine Therapy in High Risk MDS Patients,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only